Office of Research
Clinical Trials

Leading the Future of Clinical Medicine
The College of Medicine is a hub for groundbreaking clinical research. With over 30 specialized research units, our teams are dedicated to translating laboratory discoveries into life-saving clinical applications. From neurology to oncology, we provide the infrastructure and expertise necessary to push the boundaries of modern medicine.

Browse our Research Units below to view current study listings.

Clinical Trials Search

Kerri McGovern, MD

Kerri McGovern, MD

Breast Cancer

Phase 3

ShortStop HER2 Duration Study

This phase 3 study tests whether people with early HER2-positive breast cancer who have no invasive cancer left after pre-surgery chemotherapy (a pathologic complete response) can safely get a shorter course of HER2-targeted therapy. Participants are randomly assigned to receive trastuzumab (with or without pertuzumab, based on their doctor's choice) for either about 6 months or about 12 months given every three weeks by IV or as a subcutaneous shot. The trial looks mainly at whether cancer recurrence-free survival with 6 months is no worse than with 12 months. It also compares patient-reported quality of life and side effects, and tracks serious side effects, overall survival, and time to brain recurrence. Patients have heart checks and routine imaging during treatment. After treatment, people are followed every 6 months for 5 years, then yearly up to 10 years total.

This study may be appropriate for those with: Newly Diagnosed Cancer

Learn More about ShortStop HER2 Duration Study
Jennifer Leddon, MD, PhD

Jennifer Leddon, MD, PhD

Skin Cancer & Sarcoma | Breast Cancer

Phase 1

AMXT1501 and DFMO With Standard Care

This open-label Phase 1b/2 study tests two oral drugs, AMXT 1501 and DFMO, given together with standard treatments in people with advanced ER+ / HER2- breast cancer or with unresectable or metastatic cutaneous melanoma. AMXT 1501 blocks tumor uptake of polyamines and DFMO lowers polyamine production; together they aim to reduce tumor-supporting molecules and possibly improve responses to standard therapy. In the breast cancer group the combo is given with fulvestrant and capivasertib. In the melanoma group the combo is given with pembrolizumab. The Phase 1b part uses a small dose-escalation plan to find a safe dose for Phase 2. The Phase 2 part will look for signs the treatment controls or shrinks tumors using standard tumor response rules. The study also checks drug levels in blood, changes in tumor tissue and immune genes, and overall safety. About 92 patients may be enrolled across the two groups. Participants will have screening tests, regular clinic visits each treatment cycle (28 days), imaging to measure response, and follow-up visits.

This study may be appropriate for those with: Metastatic Cancer

Learn More about AMXT1501 and DFMO With Standard Care
Sarah Sittenfeld

Sarah Sittenfeld

Gynecologic Cancer

Phase 3

Adjuvant Radiation for Pleural Mesothelioma

This randomized Phase 3 study compared two approaches for treating stage I-IIIA malignant pleural mesothelioma that is suitable for pleurectomy/decortication (P/D). All patients received surgery to remove visible tumor and standard chemotherapy (pemetrexed with cisplatin or carboplatin). Half of the patients were randomly assigned to also get adjuvant hemithoracic intensity-modulated pleural radiation therapy (IMPRINT), a targeted form of radiation to the chest lining, while the other half received no additional radiation. The main goal was to see if adding IMPRINT improves overall survival. Secondary goals included measuring local control, spread to distant sites, progression-free survival, treatment-related side effects, and quality of life. The study also planned exploratory analyses of staging accuracy, surgical outcomes, biomarkers, and radiation dose effects. After treatment, patients were followed frequently for the first 2 years and then every 6 months for up to 5 years. The trial was terminated early, so only limited outcome data were available.

This study may be appropriate for those with: Newly Diagnosed Cancer

Learn More about Adjuvant Radiation for Pleural Mesothelioma
Thomas Herzog, MD

Thomas Herzog, MD

Gynecologic Cancer

Phase 3

Sac TMT Maintenance in Ovarian Cancer

This late-stage (Phase 3) study is testing a new maintenance option for people with newly diagnosed advanced ovarian cancer whose tumors are HRD-negative. Participants will have already had surgery and first-line platinum-based chemotherapy and shown no disease growth or some response. The study compares sacituzumab tirumotecan (an antibody-drug therapy) given as maintenance, with or without the targeted drug bevacizumab, to the usual standard care (which may include observation or bevacizumab maintenance). The main goal is to find out if the study treatment keeps cancer from getting worse for longer. Researchers will also track overall survival, later disease progression after new treatments, safety and side effects, and quality of life measures using standard questionnaires. Participants will have regular clinic visits for treatment, scans, and assessments during the treatment and for long-term follow-up. The full study follow-up can last several years to measure how long benefits and side effects last.

This study may be appropriate for those with: Newly Diagnosed Cancer

Learn More about Sac TMT Maintenance in Ovarian Cancer
Amanda Jackson, MD

Amanda Jackson, MD

Gynecologic Cancer

Phase 1

IMGN151 in Gynecologic Cancers

This Phase 1b study tests IMGN151, an investigational cancer drug, in adults with gynecologic cancers. About 377 people will join at about 50 sites. Participants are placed into treatment groups: IMGN151 given with carboplatin, with olaparib, with bevacizumab, or as IMGN151 alone. The main goals are to find dose‑limiting toxicities and to assess safety and side effects over the study period, and to look for early signs that tumors respond (shrink or stop growing). Participants must have good performance status, most need at least one measurable tumor by scan, and must meet timing rules for prior treatments. People with certain ovarian tumor types, prior FRα‑targeting therapy, large prior radiation to the marrow, or other significant medical issues are not allowed. The study lasts about 3 years overall. Participants will come for regular clinic visits for infusions, blood tests, and scans and will stay on treatment until disease progression, unacceptable side effects, or other reasons to stop.

This study may be appropriate for those with: Newly Diagnosed Cancer

Learn More about IMGN151 in Gynecologic Cancers
Caroline Billingsley, MD

Caroline Billingsley, MD

Gynecologic Cancer

Phase 1

Phase 2 Study of ACR-368 in Endometrial Cancer

This Phase 2 study tests ACR-368 in people with high-grade endometrial cancer. Participants are placed into one of three groups. Arms 1 and 2 use a lab test called OncoSignature to predict sensitivity to ACR-368: Arm 1 (OncoSignature Positive) receives ACR-368 alone; Arm 2 (OncoSignature Negative) receives ACR-368 plus ultra-low dose gemcitabine (ULDG). Arm 3 (no OncoSignature testing) also receives ACR-368 with ULDG; EU sites enroll only to Arm 3. Treatment continues until the cancer gets worse, side effects become unacceptable, or the person stops. The main goal is to measure tumor response by CT or MRI every 8 weeks for up to 2 years. Safety, some drug levels in blood, overall survival, time without cancer growth, and duration of any response are also tracked. Key eligibility includes prior platinum chemotherapy and prior anti-PD-(L)1 therapy, measurable disease, and adequate overall health. Certain conditions like uncontrolled viral infections, serious heart disease, recent major surgery or recent cancer treatment, symptomatic brain metastases on high-dose steroids, bowel obstruction, or prior CHK1 inhibitor use will exclude people from joining.

This study may be appropriate for those with: Relapsed / Refractory Cancer

Learn More about Phase 2 Study of ACR-368 in Endometrial Cancer
513-584-7698
Kerri McGovern, MD

Kerri McGovern, MD

Head and Neck Cancer

Phase 2

Testing Ado-Trastuzumab Emtansine Compared to the Usual Treatment for Salivary Gland Cancer

A CONTROLLED, RANDOMIZED PHASE II TRIAL OF DOCETAXEL PLUS TRASTUZUMAB VERSUS ADO-TRASTUZUMAB EMTANSINE FOR RECURRENT, METASTATIC, OR TREATMENT-NAÏVE, UNRESECTABLE HER2-POSITIVE SALIVARY GLAND CANCER

This study may be appropriate for those with: Metastatic Cancer

Learn More about Testing Ado-Trastuzumab Emtansine Compared to the Usual Treatment for Salivary Gland Cancer
Bailey Nelson

Bailey Nelson

Genitourinary Cancer

Phase 2

Bladder Preservation Immunoradiation

This Phase II study tests whether combining the immune drug pembrolizumab with radiation therapy can allow people with muscle invasive bladder cancer to keep their bladder after the tumor has already shrunk from pre-surgery chemotherapy. Eligible patients have an excellent clinical response after neoadjuvant chemotherapy and will receive daily photon radiation to the bladder Monday through Friday for up to about 4 weeks while also getting pembrolizumab through an IV every 3 weeks. Before joining, patients have had a TURBT (a bladder tumor biopsy/removal procedure) and staging scans. The study tracks how long patients keep their bladder without cancer returning, whether they later need bladder removal (salvage cystectomy), survival outcomes, side effects, and patient-reported symptoms. Blood, urine, and tissue samples will be stored for future research. After finishing treatment, participants are followed regularly for up to 5 years.

This study may be appropriate for those with: Newly Diagnosed Cancer

Learn More about Bladder Preservation Immunoradiation
Kerri McGovern, MD

Kerri McGovern, MD

Head and Neck Cancer

Phase 3

Radiation With Cetuximab or Chemotherapy

This phase 3 trial compares two treatments given with high-precision radiation therapy (IMRT) for people with advanced head and neck cancer who cannot take cisplatin. Patients are randomly placed into one of two groups. One group gets weekly cetuximab (a drug that targets the EGFR protein on some cancer cells) together with 35 daily radiation treatments over about 7 weeks. The other group gets weekly carboplatin and paclitaxel chemotherapy together with the same radiation schedule. Patients have scans and blood tests during the study and are followed after treatment at 30 days, then at 4, 6, 12, 18, 24, 30, and 36 months and then yearly. The main goal is to compare progression-free survival between the two groups. Secondary goals include comparing overall survival, side effects, where the cancer returns if it does, and changes in eating and speaking function.

This study may be appropriate for those with: Metastatic Cancer

Learn More about Radiation With Cetuximab or Chemotherapy
Olugbenga Olowokure, MD

Olugbenga Olowokure, MD

Gastrointestinal Cancer

Phase 3

Panitumumab for KRAS Wild Type Pancreas

This is a phase III randomized trial for adults with pancreatic ductal adenocarcinoma that cannot be removed by surgery or that has spread, whose tumors are KRAS wild type and BRAF V600E wild type by tissue testing. Participants are assigned to one of two groups. One group receives standard second line chemotherapy (one of several standard regimens) alone. The other group receives the same chemotherapy plus panitumumab, an antibody that targets EGFR on tumor cells. Treatment is given in 28 day cycles, typically with drug infusions on days 1 and 15, and continues until the cancer progresses or side effects are unacceptable. The main goal is to see whether adding panitumumab improves overall survival. The study also compares tumor response, progression free survival, side effects, and quality of life. Blood and tumor samples may be collected and stored for future research. Participants are followed for up to three years after randomization.

This study may be appropriate for those with: Metastatic Cancer

Learn More about Panitumumab for KRAS Wild Type Pancreas